Trump administration 340B pilot program is thwarted, for now, by U.S. appeals court

Taking stock of the drug industry, from the lab to the medicine chest

January 8, 2026 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Alex Hogan/STAT STAT+ | Trump administration 340B pilot program is thwarted, for now, by a U.S. appeals court Hospital groups filed a lawsuit arguing the pilot would cause enormous financial strain while waiting for rebates instead of upfront discounts By Ed Silverman STAT+ | Eli Lilly's Zepbound, on top of immunology drug, helped reduce psoriatic arthritis symptoms Data show that a combination treatment, including the therapy Taltz, was more effective than older therapy alone. By Elaine Chen Opinion: Do Americans expect too much from drugs? Pharma's hunt for a 'magic bullet' distracts from the fact that medicine isn't very good at treating the root causes of disease. By Thomas Goetz STAT Why this year's JPM health care conference has a different vibe Host Alex Hogan chats with STAT reporters Allison DeAngelis and Damian Garde about what to expect from upcoming JPM healthcare conference. By Alex Hogan STAT+ | Parabilis Medicines raises $305 million as CEO warms to an IPO The company, formerly known as FogPharma, is the latest biotech firm to attract crossover investors. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser